Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

康泰生物（300601）公告，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破(组分) 联合疫苗已完成III期临床试验准备工作，开启III期临床试验，并于今日成功完成首例受试者入组。该疫 苗适用于2月龄及以上的婴幼儿，用于预防百日咳、白喉、破伤风。目前，国内尚无同类产品获批上 市。 ...

| | | 债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2025-053 深圳康泰生物制品股份有限公司 关于吸附无细胞百白破（组分）联合疫苗 开启Ⅲ期临床试验的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）全资子公司北京民 海生物科技有限公司研发的吸附无细胞百白破（组分）联合疫苗已完成Ⅲ期临 床试验准备工作，开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。现 将相关情况公告如下： 一、药物基本信息 | 名称 | 剂型 | 规格 | 注册分类 | 临床试验分期 | | --- | --- | --- | --- | --- | | 吸附无细胞百白破 | 注射剂 | 0.5ml/剂 | 预防用生物制 | Ⅲ期临床试验 | | （组分）联合疫苗 | | | 品原第 4 类 | | 吸附无细胞百白破（组分）联合疫苗适用于2月龄及以上的婴幼儿，接种本 疫苗后，可使机体产生免疫应答，用于预防百日咳、白喉、破伤风。该疫苗中 的百日咳抗原可精确定量，保证有效成分的 ...

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 关于三价流感病毒裂解疫苗（MDCK 细胞） 临床试验申请获得受理的公告 | 证券代码：300601 | 证券简称：康泰生物 公告编号：2025-052 | | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | 受理号：CXSL2500428 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。自受理之日起60日内，未收到药审中心否定或质疑意见的，公司可以按照 提交的方案开展临床试验。 二、产品的基本情况 本次申请临床试验获得受理的三价流感病毒裂解疫苗（MDCK细胞）适用于3 周岁及以上人群，可刺激机体产生抗流感病毒的免疫力，用于预防疫苗相关型别 的流感病毒引起的流行性感冒。流行性感冒（也称流感）是由流感病毒引起的急 性呼吸道传染病,接种流感疫苗是预防流感疾病及流感大爆发最有效和最经济的 措施。MDCK细胞具有易培养、增殖快、流感病毒易感等特征，细胞基质流感疫苗 通过在MDCK细胞中大规模培养流感病毒，可以实现生产产量更高、产品质量更稳 定、生产成本更低的效果。 本公司及董事会全体成 ...

Group 1 - The core point of the announcement is the adjustment of the conversion price for the company's convertible bonds "Kangtai Zhuan 2" from 15.82 CNY to 15.73 CNY per share, effective from June 6, 2025 [1][2] - The adjustment is based on the company's 2024 annual equity distribution plan, which includes a cash dividend of 0.90 CNY per 10 shares, with no stock dividends or capital reserve transfers [2] - The adjustment formula used for the conversion price is P1 = P0 - D, where P0 is the previous conversion price and D is the cash dividend per share [2] Group 2 - The company issued 20 million convertible bonds on July 15, 2021, under the code "Kangtai Zhuan 2" [1] - The adjustment of the conversion price is in accordance with relevant laws and regulations, as well as the terms outlined in the bond issuance prospectus [1][2] - The effective date for the new conversion price will be the day after the equity distribution, which is June 6, 2025 [2]

证券代码：300601 证券简称：康泰生物 公告编号：2025-050 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 分派方案已经公司 2025 年 5 月 20 日召开的 2024 年度股东大会审议通过。2024 年度利润分配方案为：以 2024 年年度权益分派实施公告中确定的股权登记日当 日的总股本为基数，向全体股东每 10 股派 0.90 元（含税）现金红利，不送红股， 不以资本公积金转增股本。 事项发生变化。根据公司 2024 年度股东大会决议，本次权益分派以 2024 年年度 权益分派实施公告中确定的股权登记日当日的总股本为基数，无需调整分配比例， 公司按照分配比例不变的原则对分配总额进行调整。 原则一致。 二、本次实施的利润分配方案 公司 2024 年年度权益分派方案为：以 2024 年年度权益分派实施公告中确定 的股权登记日当日的总股本为基数，向全体股东每 10 股派 0.900000 元现金红利 （含税；扣税后，通过深股通持有股份 ...

| | | 证券代码：300601 证券简称：康泰生物 公告编号：2025-051 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 关于可转债转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 债券代码：123119 债券简称：康泰转 2 调整前"康泰转 2"转股价格为：15.82 元/股 调整后"康泰转 2"转股价格为：15.73 元/股 转股价格调整生效日期：2025 年 6 月 6 日 一、可转换公司债券转股价格调整依据 深圳康泰生物制品股份有限公司（以下简称"公司"）于 2021 年 7 月 15 日 向不特定对象发行了 2,000.00 万张可转换公司债券（债券简称：康泰转 2，债 券代码：123119）。根据相关法律法规和《深圳康泰生物制品股份有限公司向不 特定对象发行可转换公司债券募集说明书》（以下简称"募集说明书"）的相关规 定，在本次"康泰转 2"发行之后，当公司发生派送股票股利、转增股本、增发 新股（不包括因本次发行的可转债转股而增加的股本）、配股以及派发现金股利 等情况时，公司将按上 ...

证券代码：300601 证券简称：康泰生物 公告编号：2025-050 深圳康泰生物制品股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 债券代码：123119 债券简称：康泰转 2 一、股东大会审议通过利润分配方案情况 1、深圳康泰生物制品股份有限公司（以下简称"公司"）2024 年年度权益 分派方案已经公司 2025 年 5 月 20 日召开的 2024 年度股东大会审议通过。2024 年度利润分配方案为：以 2024 年年度权益分派实施公告中确定的股权登记日当 日的总股本为基数，向全体股东每 10 股派 0.90 元（含税）现金红利，不送红股， 不以资本公积金转增股本。 2、本次权益分派方案自披露至实施期间，公司股本总额可能因可转债转股 事项发生变化。根据公司 2024 年度股东大会决议，本次权益分派以 2024 年年度 权益分派实施公告中确定的股权登记日当日的总股本为基数，无需调整分配比例， 公司按照分配比例不变的原则对分配总额进行调整。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案及其调整 ...

北京│上海│深圳│杭州│广州│昆明│天津│成都│宁波│福州│西安│南京│南宁│济南│重庆│苏州│长沙│太原│武汉│贵阳│乌鲁木齐│郑州│石家庄│合肥│ 海南│青岛│南昌│大连│银川│拉孜│香港│巴黎│马德里│斯德哥尔摩│纽约│马来西亚│柬埔寨 BEIJING│SHANGHAI│SHENZHEN│HANGZHOU│GUANGZHOU│KUNMING│TIANJIN│CHENGDU│NINGBO│FUZHOU│XI'AN│NANJING│NANNING│JINAN│CHONGQING│SUZHOU│CHANGSHA│AIYUAN│WUHAN│GUIYANG│URUMQI│ ZHENGZHOU│SHIJIAZHUANG│HEFEI│HAINAN│QINGDAO│NANCHANG│DALIAN│YINCHUAN│LHATSE│HONG KONG│PARIS│MADRID│STOCKHOLM│NEW YORK│MALAYSIA│Cambodia 国浩律师（深圳）事务所 关于 深圳康泰生物制品股份有限公司 2024 年度股东大会 之 法律意见书 GLG/SZ/A4303/FY/2025-533 致：深圳康泰生物制品股份有 ...